A Phase 2 Trial of Lutikizumab, an Anti –Interleukin 1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis

ConclusionThe limited improvement of WOMAC pain and the lack of synovitis improvement with lutikizumab, together with published trial results for other IL ‐1 inhibitors, suggest that IL‐1 inhibition is not an effective analgesic/anti‐inflammatory therapy in most patients with knee OA and associated synovitis.This article is protected by copyright. All rights reserved.

https://onlinelibrary.wiley.com/doi/abs/10.1002/art.40840?af=R

Source: Arthritis and Rheumatology - January 17, 2019 Category: Rheumatology Authors: Roy M. Fleischmann, Henning Bliddal, Francisco J. Blanco, Thomas J. Schnitzer, Charles Peterfy, Su Chen, Li Wang, Sheng Feng, Philip G. Conaghan, Francis Berenbaum, Jean ‐Pierre Pelletier, Johanne Martel‐Pelletier, Ole Vaeterlein, Gurjit Tags: Full Length Source Type: research